SVE Stock Overview
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Synthaverse S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.80 |
| 52 Week High | zł6.40 |
| 52 Week Low | zł3.55 |
| Beta | 1.28 |
| 1 Month Change | 24.16% |
| 3 Month Change | 10.40% |
| 1 Year Change | -20.00% |
| 3 Year Change | -51.02% |
| 5 Year Change | 492.59% |
| Change since IPO | 0% |
Recent News & Updates
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking
Apr 20
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems
Apr 18Recent updates
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking
Apr 20Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems
Apr 18BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly
Oct 14More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%
Nov 29We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings
Nov 16Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?
May 02Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?
Mar 08What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?
Jan 29
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 03BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt
Dec 07Shareholder Returns
| SVE | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 1.2% | -0.7% | 1.4% |
| 1Y | -20.0% | -18.5% | 26.6% |
Return vs Industry: SVE underperformed the Polish Biotechs industry which returned -18.5% over the past year.
Return vs Market: SVE underperformed the Polish Market which returned 26.6% over the past year.
Price Volatility
| SVE volatility | |
|---|---|
| SVE Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.8% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: SVE's share price has been volatile over the past 3 months.
Volatility Over Time: SVE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 239 | Mieczyslaw Starkowicz | www.synthaverse.pl |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.
Synthaverse S.A. Fundamentals Summary
| SVE fundamental statistics | |
|---|---|
| Market cap | zł338.51m |
| Earnings (TTM) | zł4.76m |
| Revenue (TTM) | zł58.61m |
71.1x
P/E Ratio5.8x
P/S RatioIs SVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVE income statement (TTM) | |
|---|---|
| Revenue | zł58.61m |
| Cost of Revenue | zł23.82m |
| Gross Profit | zł34.78m |
| Other Expenses | zł30.03m |
| Earnings | zł4.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 22, 2024
| Earnings per share (EPS) | 0.067 |
| Gross Margin | 59.35% |
| Net Profit Margin | 8.12% |
| Debt/Equity Ratio | 59.3% |
How did SVE perform over the long term?
See historical performance and comparison